Dr Reddy’s Pins Hopes On Complex Drugs Pipeline Amid Weak Q3
Executive Summary
Dr Reddy’s Laboratories is betting on complex product launches to power an improvement in its bottom line after reporting a 29% drop in quarterly net profit, hit by price erosion in its main US market.
You may also be interested in...
Ex-Teva Executive To Steer Dr Reddy’s As COO
Erez Israeli, ex-Teva long-timer, is set to take over as Dr Reddy’s chief operating officer and global head of the generics and PSAI (pharmaceuticals services and active ingredients) businesses. Israeli’s appointment comes at a time when the Indian firm tackles multiple operational challenges, including compliance issues at its plants.
Dr Reddy’s Charts Sharp Cost Overhaul Amid Weak Q1
Dr Reddy’s plans a significant review of its “cost structure”, including potential portfolio rationalization and R&D site optimization, as part of broader efforts to emerge “leaner and agile” as it grapples with multiple business challenges that saw it post disappointing first quarter earnings.
Top US Court Lifts Discovery Stay On Price-Fixing
The US Supreme Court has lifted a stay on document discovery in a multi-state lawsuit in which dozens of generics companies – including Teva, Mylan and Pfizer – are accused of price fixing. The ruling will allow a swathe of documents to be released in what Connecticut’s attorney general has said is potentially “the largest cartel case” in US history.